Stock INMED PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News InMed Pharmaceuticals Inc Deutsche Boerse AG

Equities

CA13764X1069

End-of-day quote Deutsche Boerse AG
Other stock markets
- EUR - Intraday chart for InMed Pharmaceuticals Inc
05-14 Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M MT
05-14 InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
InMed Pharmaceuticals : Material Agreement Form 8 K
PU
InMed Pharmaceuticals : INM-901 Drug Candidate in Development for Alzheimer’s Disease
PU
InMed to Present at the Emerging Growth Conference
NE
Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M
MT
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
NE
InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
NE
InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board
CI
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
NE
InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease
CI
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
NE
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
NE
InMed Pharmaceuticals Inc. Provides Update on Pharmaceutical Development Programs
CI
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
NE
InMed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
CI
InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024
CI
InMed Pharmaceuticals Inc. Announces Executive Changes, Effective February 20, 2024
CI
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
NE
Transcript : InMed Pharmaceuticals Inc. - Special Call
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
NE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INM Stock
  4. Stock
  5. News InMed Pharmaceuticals Inc